24.09.2025 • News

Management Change at Tesa: Bahrami Succeeds Goldberg

The Supervisory Board of Tesa has appointed Kourosh Bahrami as the new CEO. He will take over the position on October 1, 2025 from Norman Goldberg, who is leaving the company at his own request.

Norman Goldberg has been CEO since 2020 and was previously a member of Tesa's Executive Board as Chief Industrial Officer since 2017. During this time, he played a key role in shaping the transformation of the Beiersdorf subsidiary into a global adhesive solutions company. With his focus on innovation, sustainability, digitalization and technical excellence, he has provided important impetus and strengthened the company's position in the market.

"Leading Tesa in recent years has been a real privilege," says Goldberg. "Together with a dedicated global team, we have accelerated innovation, expanded internationally and positioned the company stronger than ever for an innovative and sustainable future."

Bahrami has more than 30 years of international leadership and entrepreneurial experience in both the B2B and B2C sectors. He worked for the Henkel Group for more than 25 years, most recently as President/Global Business Head Adhesive Technologies Industrial for the Loctite industrial adhesives business. His expertise includes sales, marketing and supply chain as well as a deep understanding of key customer markets such as automotive, industrial maintenance and repair and Industry 4.0 applications.

Bahrami has lived and worked in Europe, the United States and Asia. He holds a degree in Business Administration and Management from the University of Cologne and HEC Paris, followed by a PhD from the University of Vienna and an executive program at Harvard Business School.

Company

Tesa SE

Hugo-Kirchberg-Straße 1
22848 Norderstedt
Germany

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read